UNDERWRITING AGREEMENTUnderwriting Agreement • January 20th, 2011 • Dendreon Corp • Pharmaceutical preparations • New York
Dendreon Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to J.P. Morgan Securities LLC and each of the other underwriters, if any, named on Schedule II hereto (each a “Note Underwriter” and collectively, the “Note Underwriters”), for whom J.P. Morgan Securities LLC is acting as representative (the “Representative”), $540,000,000 aggregate principal amount of its 2.875% Convertible Senior Notes due 2016 (the “Underwritten Securities”) and, at the option of the Note Underwriters, up to an additional $80,000,000 aggregate principal amount of its 2.875% Convertible Senior Notes due 2016 (the “Option Securities”) if and to the extent that you, as the Representative of the Note Underwriters, shall have determined to exercise the option to purchase such 2.875% Convertible Senior Notes due 2016 granted to the Note Underwriters in Section 2 hereof. The Underwritten Securities and, if and to the extent issued, the Option Securities are herein referred to as the “S
